<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0001-6002</journal-id>
<journal-title><![CDATA[Acta Médica Costarricense]]></journal-title>
<abbrev-journal-title><![CDATA[Acta méd. costarric]]></abbrev-journal-title>
<issn>0001-6002</issn>
<publisher>
<publisher-name><![CDATA[Colegio de Médicos y Cirujanos de Costa Rica]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0001-60022017000300090</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Medicina basada en evidencias: el caso de las cifras meta de presión arterial]]></article-title>
<article-title xml:lang="en"><![CDATA[Evidence based medicine: the case of blood pressure targets]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Arguedas-Quesada]]></surname>
<given-names><![CDATA[José Agustín]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Costa Rica Escuela de Medicina Departamento de Farmacología y Toxicología Clínica]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Costa Rica</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2017</year>
</pub-date>
<volume>59</volume>
<numero>3</numero>
<fpage>90</fpage>
<lpage>94</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_arttext&amp;pid=S0001-60022017000300090&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_abstract&amp;pid=S0001-60022017000300090&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_pdf&amp;pid=S0001-60022017000300090&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen El concepto de &#8220;Medicina basada en evidencias&#8221;, que ha adquirido mayor trascendencia en el transcurso de los últimos años, se apoya en el postulado de que la enseñanza y la práctica clínica de la medicina, así como la definición de las políticas de salud a nivel poblacional, deben estar respaldadas por evidencias científicas sólidas, que demuestren que existe una adecuada relación entre los beneficios y los potenciales inconvenientes asociados con la implementación práctica de cualquier intervención preventiva, diagnóstica o terapéutica. Lamentablemente, en la realidad muchas de las acciones usuales en la práctica médica no cumplen con esas condiciones, lo que puede resultar en una utilización inapropiada de los recursos disponibles y en la exposición de los pacientes a riesgos innecesarios. La &#8220;medicina basada en evidencias&#8221; parte de un análisis crítico exhaustivo de los diversos estudios clínicos que hayan evaluado una cuestión específica, con el fin de identificar la evidencia de mayor calidad y solidez científica disponible, y a partir de ahí, realizar una cuantificación que permita establecer si la balanza de los beneficios y de los riesgos justifica su aplicación clínica. Además, es un proceso dinámico, cuyos resultados pueden irse modificando paulatinamente, con el objetivo de mejorar la atención médica, a medida que surgen nuevas evidencias de calidad. El caso de las cifras meta de presión arterial usadas en el tratamiento de la hipertensión arterial, es un tópico que ha sido sometido en años recientes al proceso de análisis de las evidencias; como resultado, han ocurrido cambios e implicaciones a nivel clínico y académico, y sirve de ejemplo para ilustrar el proceso descrito.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract The concept of &#8220;Evidence Based Medicine&#8221;, which has achieved greater importance during the last years, is based on the idea that teaching and practicing clinical medicine, as well as the definition of health policies at the population level, should be supported by solid scientific evidences showing that there is an adequate relationship between the benefits and potential risks associated with the practical implementation of any preventive, diagnostic, or therapeutic intervention. Unfortunately, many of the usual actions in medical practice do not fulfill those conditions, which may result in inappropriate use of available resources and exposure of patients to unnecessary risks. &#8220;Evidence Based Medicine&#8221; starts from an exhaustive critical inquiry of the clinical studies that have evaluated a specific issue, in order to identify the available evidence with higher quality and scientific support, and from there to perform a quantitative analysis that allows determining if the benefits/risks balance justifies its clinical application. In addition, it is a dynamic process, whose results can be gradually modified as new quality evidence emerges, with the final objective of improving medical care. The case of blood pressure targets used in the treatment of arterial hypertension is a topic that has been subjected in recent years to the process of analysis of the evidence. As a result, changes and implications have occurred both at clinical and academic levels, and it serves as an example to illustrate the process described above.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[medicina basada en evidencias]]></kwd>
<kwd lng="es"><![CDATA[cifras meta de presión arterial]]></kwd>
<kwd lng="es"><![CDATA[hipertensión arterial]]></kwd>
<kwd lng="en"><![CDATA[evidence based medicine]]></kwd>
<kwd lng="en"><![CDATA[blood pressure targets]]></kwd>
<kwd lng="en"><![CDATA[arterial hypertension]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<collab>Evidence Based Medicine Working Group</collab>
<article-title xml:lang=""><![CDATA[Evidence-based medicine: a new approach to teaching the practice of medicine]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>1992</year>
<volume>268</volume>
<page-range>2420-5</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Laurent]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guidelines from the British Hypertension Society. The lower the pressure the better]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2004</year>
<volume>328</volume>
<page-range>593-4</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<collab>Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure</collab>
<article-title xml:lang=""><![CDATA[The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2003</year>
<volume>289</volume>
<page-range>2560-72</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<collab>World Health Organization, International Society of Hypertension Writing Group</collab>
<article-title xml:lang=""><![CDATA[2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension]]></article-title>
<source><![CDATA[J Hypertens]]></source>
<year>2003</year>
<volume>21</volume>
<page-range>1983-92</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<collab>Kidney Disease Outcomes Quality Initiative (K/DOQI)</collab>
<article-title xml:lang=""><![CDATA[K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease]]></article-title>
<source><![CDATA[Am J Kidney Dis]]></source>
<year>2004</year>
<volume>43</volume>
<numero>^s5</numero>
<issue>^s5</issue>
<supplement>5</supplement>
<page-range>S1-290</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Poulter]]></surname>
<given-names><![CDATA[NR]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[British Hypertension Society Guidelines for hypertension management 2004 (BHS-IV): summary]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2004</year>
<volume>328</volume>
<page-range>634-40</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mancia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[De Backer]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Domiiczak]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2007 Guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)]]></article-title>
<source><![CDATA[J Hypertension]]></source>
<year>2007</year>
<volume>25</volume>
<page-range>1105-87</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosendorff]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Black]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
<name>
<surname><![CDATA[Cannon]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of hypertension in the prevention and management of ischemic heart disease. A scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2007</year>
<volume>115</volume>
<page-range>2761-88</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lewington]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Clarke]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Qizilbash]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual data for one million adults in 61 prospective studies]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2002</year>
<volume>360</volume>
<page-range>1903-13</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gueyffier]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Observational epidemiological studies: values and limitations]]></article-title>
<source><![CDATA[J Hypertens]]></source>
<year>2001</year>
<volume>21</volume>
<page-range>673-5</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MacMahon]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Collins]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2001</year>
<volume>357</volume>
<page-range>455-62</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hansson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Zanchetti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Carruthers]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1998</year>
<volume>351</volume>
<page-range>1755-62</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<collab>UK Prospective Diabetes Study Group</collab>
<article-title xml:lang=""><![CDATA[Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>1998</year>
<volume>317</volume>
<page-range>703-13</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arguedas]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Perez]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
<name>
<surname><![CDATA[Wright]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<source><![CDATA[Treatment blood pressure targets for hypertension.]]></source>
<year></year>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arguedas]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Blood pressure targets: are clinical guidelines wrong?]]></article-title>
<source><![CDATA[Curr Op Cardiol]]></source>
<year>2010</year>
<volume>25</volume>
<page-range>350-4</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Filippone]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Foy]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Newman]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Goal directed antihypertensive therapy: lower may not always be better]]></article-title>
<source><![CDATA[Clev Clin J Med]]></source>
<year>2011</year>
<volume>78</volume>
<page-range>123-33</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grossman]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Blood pressure: the lower, the better. The con side.]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2011</year>
<volume>34</volume>
<numero>^s2</numero>
<issue>^s2</issue>
<supplement>2</supplement>
<page-range>308-12</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arguedas]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Leiva]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Wright]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Blood pressure targets for hypertension in people with diabetes mellitus]]></article-title>
<source><![CDATA[Cochrane Database of Systematic Reviews]]></source>
<year>2013</year>
<numero>10</numero>
<issue>10</issue>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mancia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Fagard]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Narkiewicz]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2013 ESH/ESC Guidelines for the management of arterial hypertension; the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)]]></article-title>
<source><![CDATA[J Hypertens]]></source>
<year>2013</year>
<volume>31</volume>
<page-range>1281-357</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[James]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Oparil]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Carter]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evidence based guideline for the management of high blood pressure in adults. Report from the panel members appointed to the Eighth Joint National Committee (JNC 8)]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2014</year>
<volume>311</volume>
<page-range>507-20</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weber]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Schiffrin]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[White]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical practice guideline for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension]]></article-title>
<source><![CDATA[J Hypertens]]></source>
<year>2014</year>
<volume>32</volume>
<page-range>3-15</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<collab>American Diabetes Association</collab>
<article-title xml:lang=""><![CDATA[Cardiovascular disease and risk management]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2016</year>
<volume>39</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>S60-71</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<collab>JATOS Study Group.</collab>
<article-title xml:lang=""><![CDATA[Principal results of the Japanese Trial to Assess Optimal Systolic blood pressure in elderly hypertensive patients (JATOS).]]></article-title>
<source><![CDATA[Hypertens Res]]></source>
<year>2008</year>
<volume>31</volume>
<page-range>2115-27</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ogihara]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Saruta]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Rakugi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study]]></article-title>
<source><![CDATA[Hypertension]]></source>
<year>2010</year>
<volume>56</volume>
<page-range>196-202</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<collab>The Heart Outcomes Prevention Evaluation Study Investigators</collab>
<article-title xml:lang=""><![CDATA[Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients]]></article-title>
<source><![CDATA[N Eng J Med]]></source>
<year>2000</year>
<volume>342</volume>
<page-range>145-53</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<collab>The European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators</collab>
<article-title xml:lang=""><![CDATA[Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicenter trial (the EUROPA Study)]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2003</year>
<volume>362</volume>
<page-range>782-8</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arguedas]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Does our understanding of blood pressure targets in diabetes need rethinking?]]></article-title>
<source><![CDATA[Diabetes Management]]></source>
<year>2014</year>
<volume>4</volume>
<page-range>215-8</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<collab>The SPRINT Research Group</collab>
<article-title xml:lang=""><![CDATA[A randomized trial of intensive versus standard blood-pressure control]]></article-title>
<source><![CDATA[N Eng J Med]]></source>
<year>2015</year>
<volume>373</volume>
<page-range>2103-16</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xie]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Atkins]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Lv]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and metaanalysis]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2016</year>
<volume>387</volume>
<page-range>435-43</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Laurent]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Boutouyrie]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Blood pressure lowering trials: wrapping up the topic?]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2016</year>
<volume>387</volume>
<page-range>923-4</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<collab>The ACCORD Study Group</collab>
<article-title xml:lang=""><![CDATA[Effects of intensive blood-pressure control in type- 2 diabetes mellitus]]></article-title>
<source><![CDATA[N Eng J Med]]></source>
<year>2010</year>
<volume>362</volume>
<page-range>1575-85</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<collab>The SPS3 Study Gr</collab>
<article-title xml:lang=""><![CDATA[Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2013</year>
<volume>382</volume>
<page-range>507-15</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
